Clinical efficacy and pregnancy outcomes of fertility-preserving re-treatment after recurrence of the patient with atypical endometrial hyperplasia and early stage endometrial carcinoma
10.3760/cma.j.issn.0529-567X.2020.01.005
- VernacularTitle: 子宫内膜非典型增生及早期子宫内膜癌复发后再次保留生育功能治疗的临床疗效及妊娠结局
- Author:
Yijiao HE
1
;
Yiqin WANG
1
;
Huiru TANG
2
;
Mian HE
3
;
Yang RAO
4
;
Rong ZHOU
1
;
Jianliu WANG
1
Author Information
1. Department of Obstetrics and Gynecology, Peking University People′s Hospital, Beijing 100044, China
2. Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital, Shenzhen 518036, China
3. Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
4. Department of Gynecological Oncology, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin 300100, China
- Publication Type:Clinical Trail
- Keywords:
Endometrial neoplasms;
Endometrial hyperplasia;
Neoplasm recurrence, local;
Fertility preservation;
Progestins;
Pregnancy outcome
- From:
Chinese Journal of Obstetrics and Gynecology
2020;55(1):21-28
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical efficacy and pregnancy outcomes of fertility- preserving re-treatment in patients with recurrent atypical endometrial hyperplasia (AEH) and early stage endometrial carcinoma (EEC) after achieved complete remission (CR) of primary fertility-preserving therapy.
Methods:There were 104 cases of AEH and EEC collected from 9 hospitals in the multi-center research network platform of fertility-preserving therapy of endometrial carcinoma in China from January 2005 to May 2019. Thirth-one cases of them relapsed from four hospitals mentioned above,who achieved CR after primary fertility-preserving therapy,was analyzed retrospectively. Of the 31 cases, 27 cases chose fertility-preserving re-treatment. The demographic characteristics, re-treatment effect, clinical factors and pregnancy outcomes were observed.
Results:(1) There were 16 AEH cases and 11 ECC cases among 27 recurrent patients who chose fertility-preserving therapy again. After re-treatment, CR was found in 13 out of 16 cases of AEH and 9 out of 11 cases of EEC. The overall CR rate was 81% (22/27). (2) After CR of recurrence, 5 cases (23%, 5/22) of re-recurrence were found after with a median time of 33 months (range 21-80 months). There were 4 cases underwent comprehensive surgical staging, and 1 patient chose the third round of fertility preservation therapy with fully informed consent, and CR was reached after 15 months. (3) There were 16 cases with pregnancy intention, with a total of 12 pregnancies, including 5 cases were natural pregnancy and 7 cases were assisted reproductive technology pregnancy. There were 5 live births. The follow-up time was up to May 2019, and the median follow-up time was 73 months (range 0-123 months). All 27 patients had disease free survival.
Conclusions:Recurrent patients with AEH and EEC after achieving successful fertility-preserving therapy could choose fertility-preserving therapy again with comprehensive assessment and fully informed consent. After re-treatment, there is a certain tumor CR rate and pregnancy rate, while the close follow-up is required during treatment.
